富瑞金融：看好艾迪康(09860)AI战略布局和Crown Bioscience并购予以“买入”评级目标价看高至12.6港元

智通财经01-26

智通财经APP获悉，富瑞金融发表研报，给予艾迪康控股(09860)“买入”评级，目标价为12.60港元。该行表示，艾迪康在AI医疗检测领域的战略布局及拟收购Crown Bioscience的重大举措，将显著强化公司在药物研发与诊断价值链中的综合实力。报告指出，艾迪康的AI战略围绕三大支柱展开：其一，AI辅助病理阅片系统能将切片读取效率提升至人工的6-7倍，并具备自动识别和纠正报告中的笔误、解剖部位...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2606986372?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-26 11:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606986372","market":"fut","top_or_hot":-1,"title":"富瑞金融：看好艾迪康(09860)AI战略布局和Crown Bioscience并购 予以“买入”评级目标价看高至12.6港元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，富瑞金融发表研报，给予艾迪康控股(09860)“买入”评级，目标价为12.60港元。该行表示，艾迪康在AI医疗检测领域的战略布局及拟收购Crown Bioscience的重大举措，将显著强化公司在药物研发与诊断价值链中的综合实力。报告指出，艾迪康的AI战略围绕三大支柱展开：其一，AI辅助病理阅片系统能将切片读取效率提升至人工的6-7倍，并具备自动识别和纠正报告中的笔误、解剖部位...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1397174.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>富瑞金融：看好艾迪康(09860)AI战略布局和Crown Bioscience并购 予以“买入”评级目标价看高至12.6港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n富瑞金融：看好艾迪康(09860)AI战略布局和Crown Bioscience并购 予以“买入”评级目标价看高至12.6港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-26 11:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1397174.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，富瑞金融发表研报，给予艾迪康控股(09860)“买入”评级，目标价为12.60港元。该行表示，艾迪康在AI医疗检测领域的战略布局及拟收购Crown Bioscience的重大举措，将显著强化公司在药物研发与诊断价值链中的综合实力。报告指出，艾迪康的AI战略围绕三大支柱展开：其一，AI辅助病理阅片系统能将切片读取效率提升至人工的6-7倍，并具备自动识别和纠正报告中的笔误、解剖部位...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1397174.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09860","symbol_name":"艾迪康控股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1397174.html","article_id":"2606986372","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606986372","pubTimestamp":1769397473,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，富瑞金融发表研报，给予艾迪康控股“买入”评级，目标价为12.60港元。该行表示，艾迪康在AI医疗检测领域的战略布局及拟收购Crown Bioscience的重大举措，将显著强化公司在药物研发与诊断价值链中的综合实力。值得注意的是，艾迪康于2025年11月宣布以最高2.04亿美元的对价收购Crown Bioscience。交易完成后，预计艾迪康约23%的收入将来自海外市场。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"159940":"金融","09860":"艾迪康控股"},"translate_title":"Jefferies Financial: Optimistic about Aidikang (09860) AI strategic layout and Crown Bioscience merger and acquisition, giving a \"buy\" rating, and the target price is as high as HK $12.6","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159940":1.5,"09860":1.5},"content_text":"智通财经APP获悉，富瑞金融发表研报，给予艾迪康控股(09860)“买入”评级，目标价为12.60港元。该行表示，艾迪康在AI医疗检测领域的战略布局及拟收购Crown Bioscience的重大举措，将显著强化公司在药物研发与诊断价值链中的综合实力。报告指出，艾迪康的AI战略围绕三大支柱展开：其一，AI辅助病理阅片系统能将切片读取效率提升至人工的6-7倍，并具备自动识别和纠正报告中的笔误、解剖部位错误及诊断遗漏的质量控制功能。其二，公司推出了面向临床医生的生成式AI实验室助手“艾小医”以及与华为联合开发的临床大语言模型“问医”，这些工具已整合到诊疗工作流程中，服务于报告质控、流式细胞分析及患者智能诊断门户。其三，艾迪康已完成了其长达20年的精准医学检测数据的阶段性质整合、治理与清洗，并正积极探索其在商业保险等领域的商业化机会。公司目前每年完成约1000万次AI辅助影像解读。值得注意的是，艾迪康于2025年11月宣布以最高2.04亿美元的对价收购Crown Bioscience。该交易包括1.2亿美元的首期付款及基于业绩目标的递延支付。据了解，Crown Bioscience专注于转化肿瘤学与免疫肿瘤学领域，拥有全球最大的商业PDX模型库，在CDX模型及生物标志物解决方案领域具备深厚积累，服务于全球1100余家客户(含全球前20大制药企业)。此外，Crown在AI领域布局领先，拥有行业首个临床前数据平台及先进的抗癌药物协同预测工具。富瑞金融认为，此次收购将大幅提升艾迪康在临床前及转化研究方面的能力，并通过Crown丰富的数据资产和生物信息学专长进一步巩固其行业地位。交易完成后，预计艾迪康约23%的收入将来自海外市场。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606986372","isCrawlerRequest":true}

富瑞金融：看好艾迪康(09860)AI战略布局和Crown Bioscience并购 予以“买入”评级目标价看高至12.6港元

精彩评论

富瑞金融：看好艾迪康(09860)AI战略布局和Crown Bioscience并购予以“买入”评级目标价看高至12.6港元